Prelude Therapeutics Incorporated (PRLD) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -21.68M | 23.12M | -19.11M | -26.07M | -34.23M | -20.74M | -27.3M | -23.06M | -31.79M | -23.58M | -25.68M | -27.67M |
| Operating CF Margin % | -473.47% | 409.91% | -294.08% | - | - | -518.6% | -909.87% | - | - | - | - | - |
| Operating CF Growth % | 36.65% | 211.45% | 29.97% | -13.09% | -7.68% | 12.02% | -6.28% | 16.67% | -5.5% | -2.84% | -25.66% | -49.82% |
| Net Income | -10.38M | -16.46M | -19.73M | -31.23M | -32.09M | -28.73M | -32.27M | -34.74M | -31.43M | -33.08M | -30.61M | -30.43M |
| Depreciation & Amortization | 391K | 285K | 425K | 433K | 435K | 489K | -3.28M | 452K | 426K | 331K | 279K | 723K |
| Stock-Based Compensation | 0 | 1.84M | 2.42M | 3.81M | 3.83M | 3.77M | 12.02M | 6.1M | 5.55M | 5.91M | 6.71M | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.07M | -1.6M | 0 |
| Other Non-Cash Items | 2M | 329K | 334K | 170K | 463K | -563K | -2.9M | -935K | -1.13M | 608K | 454K | 6.37M |
| Working Capital Changes | -13.69M | 37.12M | -2.57M | 739K | -6.88M | 4.29M | -862K | 6.07M | -5.21M | 3.72M | -926K | -4.33M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -1.88M | 1.27M | -2.43M | -850K | -1.91M | 1.81M | -213K | 1.08M | 631K | -465K | -472K | -1.71M |
| Cash from Investing | 8.5M | -60.34M | 40.09M | 11.52M | 62.19M | 22.12M | 10.73M | 26.12M | 31.22M | 7.74M | 15.04M | -75.43M |
| Capital Expenditures | 0 | 0 | 0 | -20K | -47K | -53K | -63K | -359K | -289K | -1.13M | -591K | -983K |
| CapEx % of Revenue | - | - | - | - | - | 1.32% | 2.1% | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -8.87K | -15.64K | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.87K | 15.64K | 0 |
| Cash from Financing | -314K | 24.94M | -5K | 37K | -160K | -34K | -131K | 59K | -14K | 25.24M | 88K | 111.34M |
| Debt Issued (Net) | 0 | 0 | 0 | -53K | -155K | -151K | -148K | -96K | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | -263K | 24.95M | 0 | 92K | -5K | 124K | 30K | 0 | 2K | 24.94M | 104K | 111.34M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | -5K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -51K | -5K | -5K | -2K | 0 | -7K | -13K | 155K | -16K | 301K | -16K | 0 |
| Net Change in Cash | -13.5M | -12.28M | 20.97M | -14.52M | 27.8M | 1.34M | -16.69M | 3.12M | -584K | 9.39M | -10.55M | 8.24M |
| Free Cash Flow | -21.68M | 23.12M | -19.11M | -26.09M | -34.28M | -20.8M | -27.36M | -23.42M | -32.08M | -24.71M | -26.27M | -28.65M |
| FCF Margin % | -473.47% | 409.91% | -294.08% | - | - | -519.93% | -911.97% | - | - | - | - | - |
| FCF Growth % | 36.74% | 211.17% | 30.13% | -11.44% | -6.85% | 15.83% | -4.13% | 18.27% | -3.67% | -5.95% | -23.03% | -49.02% |
| FCF per Share | -0.26 | 0.37 | -0.25 | -0.34 | -0.45 | -0.27 | -0.36 | -0.31 | -0.42 | -0.36 | -0.39 | -0.51 |
| FCF Conversion (FCF/Net Income) | 2.09x | -1.40x | 0.97x | 0.83x | 1.07x | 0.72x | 0.85x | 0.66x | 1.01x | 0.71x | 0.84x | 0.91x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |